Применение фторхинолонов в лечении внебольничных и внутрибольничных пневмоний

1. Белоусов Ю.Б., Гуткин А.Б., Соколов А.В. и др. Клиническая и фармакокинетическая оценка офлоксацина при разных режимах введения у больных с бронхолегочной инфекцией / / Антибиотики и химиотер.— 1996.— Т.41, № 9.— С.47—49.

2. Andriole V.T. The Quinolones.— San Diego, 1998.— P.229—246.

3. Braun P.D., Lerner S.A. Community-acquired pneumonia / / Lancet.— 1998.— Vol.352.— P.1295—1302.

4. Byl B., Kaufman L., Jacobs F. et a l. Ciprofloxacin versus comparative antibiotics in LRTI. A meta-analysis / / Drugs.— 1993.— Vol.45.— Suppl.— P.50—51.

5. Campell G.D., Niederman M.S., Broughton W.A. et al. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement / / Amer. J. Respir. Crit. Care Med — 1996.— Vol.153.— P.1711 — 1725.

6. Carbon C., Rubinstein E. Sparfloxacin Monograph.— Chester 1994.— P.23—27.

7. Cruciani М., Basetti D. The fluoroquinolones as treatment for infection caused by gram-positive bacteria / / J. antimicrob. Chemother.— 1994.— Vol.33.— P.403—417.

8. File T.M., Segreti J., Dunbar L. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia / / Antimicrob. Agents Chemother.— 1997.— Vol.41.— P .1965—1972.

9. Finch R. The role of new quinolones in the treatment of respiratory tract infections / / Drugs.— 1995.— Vol.49.— Suppl.— P. 144—151.

10. Fink M.P., Snydman D.R., Niederman M.S. et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin / / Antimicrob. Agents Chemother.— 1994.— Vol.38.— P.547—557.

11. Forrest A., Nix D., Fallow C. et al. Pharmacodynamics of IV ciprofloxacin in seriously ill patients / / Ibid.— 1993.— Vol.37.— P.1073—1081.

12. Friedland I.R., McCracken G.H. Management of infections caused by antibiotic-resistant Streptococcus pneumonia / / New Engl. J. Med.— 1994.— Vol.331.— P.377—382.

13. Gentry L.O., Rodriguez-Gomez G., Kohler R.B. et al. Parenteral followed by oral ofloxacin for nosocomial and community-acquired pneumonia requiring hospitalization / / Amer. Rev. Respir. Dis.— 1992,— Vol.145.— P.31—35.

14. Giamarellou N. Activity of quinolones against gram-positive cocci: clinical features / / Drugs.— 1995.— Vol.49.— Suppl.— P.58—66.

15. Graham D., Klein T. et al. and the Trovan Nosocomial Pneumonia Study Group. A double-blind, randomized, multicenter study in nosocomial pneumonia (N O S) comparing trovafloxacin with ciprofIoxacin±clindamicin/metronidazole J / Interscience Conference on Antimicrobial Agents and Chemotherapy, 37-th.— Toronto, 1997.— Abstr. LM-74.

16. Guay D.R.P. Quinolones / / Antimicrobial Therapy in the Elderly Patient.— New York, 1994.— P.237—310.

17. Hendershot E. Fluoroquinolones / / Infect. Dis. Clin. N. Amer.— 1995.— Vol.9.— P.715—730.

18. Khan F., Basir R. Sequential intravenous-oral administration of ciprofloxacin vs. ceftazadime in serious bacterial respiratory tract infections / / Chest.— 1989.— Vol.96.— P.528—537.

19. Niederman M.S., Traub S.L., Ellison W. et al. A double-blind, randomized, multicenter, global study in hospitalized communityacquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone and erythromycin / / Interscience Conference on Antimicrobial Agents and Chemotherapy, 37-th.— Toronto, 1997.— Abstr. LM-72.

20. Johnson R.H., Levine S., Traub S.L. et al. Sequential intravenous/oral ciprofloxacin compared to parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia / / Infect. Dis. clin.Pract.— 1996.— Vol.5.— P.265—272.

21. Petermann W. Ofloxacin in lower respiratory tract infections / / Infection.— 1991.— Vol.19.— Suppl.— P.S372—S377.

22. Thomas J.K., Forrest A., Bhavnani S.Ai. et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy / / Antimicrob. Agents Chemother.— 1998.— Vol.42.— P.521—527.

23. Trenholme G.M., Schmitt B.A., Spear J. et al. Randomized study of intravenous/oral ciprofloxacin versus ceftazadime in the treatment of hospital and nursing home patients with lower respiratory tract infections / / Amer. J. Med.— 1989.— Vol.87.— Suppl.5A.— P.116—118.

24. Wagstaff A.J., Balfour J.A. Grepafloxacin / / Drugs.— 1997.— Vol.53.— P.817—824.

25. Wakabayashi E., Mitsuhashi S. In vitro antibacterial activity of gatifloxacin a novel 6-fluoro-8-methoxy quinolone / / Antimicrob. Agents Chemother.— 1994.— Vol.38.— P.594—601.

26. Woodhead M . Pneum onia in the e ld e rly / / J. antim icrob. Chemother — 1994 — Vol.34.— S up pl.A .— P .85—92.